

doi: 10.13241/j.cnki.pmb.2014.28.028

## 胱抑素在肾综合征出血热患者中的动态变化及意义

康 岚<sup>1</sup> 赵 波<sup>2</sup> 颜炳柱<sup>1△</sup> 杨宝山<sup>1</sup> 陈立艳<sup>1</sup> 毕蔓茹<sup>1</sup>

(1 哈尔滨医科大学附属二院感染科 黑龙江哈尔滨 150086; 2 哈尔滨医科大学附属四院中心导管室 黑龙江哈尔滨 150001)

**摘要 目的:**观察肾综合征出血热(HFRS)患者血清胱抑素的动态变化,并探讨其临床意义。**方法:**选取2010年10月至2013年6月哈尔滨医科大学附属第二医院感染科住院肾综合征出血热患者106例为研究对象,按病期(发热期、极期、多尿期、恢复期)采集血液标本,采用免疫比浊法检测血清胱抑素(CysC)水平,用全自动生化仪分析血尿素氮(BUN)、血肌酐(SCr)水平,比较不同分期及分型HFRS患者的CysC的水平,并分析CysC与BUN和SCr的相关性。**结果:**HFRS患者血清CysC各期均明显高于健康对照组( $P<0.05$ ),病程极期时达高峰,多尿期时开始下降,恢复期时明显降低但仍高于对照组;重症组患者在发病早期和极期时均显著高于轻症组( $P<0.05$ )。CysC与BUN和SCr的Pearson相关系数分别为 $r=0.7688$ 和 $r=0.8071$ ( $P<0.05$ ),CysC与BUN和SCr之间有很好的正相关性。**结论:**血清CysC可较为敏感地反映HFRS患者肾脏损伤,其检测对于病情的发展和预后判断均有重要的临床意义。

**关键词:**血清胱抑素 C;肾综合征出血热;肾脏损伤

中图分类号:R512.8 文献标识码:A 文章编号:1673-6273(2014)28-5511-03

## Clinical Significance and Dynamic Changes of CysC in Patients Suffering from Hemorrhagic Fever with Renal Syndrome (HFRS)

KANG Lan<sup>1</sup>, ZHAO Bo<sup>2</sup>, YAN Bing-zhu<sup>1△</sup>, YANG Bao-shan<sup>1</sup>, CHEN Li-yan<sup>1</sup>, BI Manru<sup>1</sup>

(1 Department of Infectious Diseases, The Second Hospital of Harbin Medical University, Harbin, Heilongjiang, 150086, China;

2 Central Catheter Room, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China)

**ABSTRACT Objective:** To study the dynamic changes of CysC and investigate the clinical significance in patients with HFRS.

**Methods:** A total of 106 patients with HFRS admitted to department of infectious diseases were enrolled in this study from October 2010 to June 2013. Blood samples were collected at different phases of HFRS, and the levels of serum CysC, BUN and SCr were tested with different methods. The levels of CysC were compared in patients among different stages and phases of HFRS, and the correlation was analyzed. **Results:** The levels of serum CysC in patients with HFRS increased significantly in febrile phase, reached its peak in hypotensive and oliguric phase and then decreased gradually in diuretic phase but still higher than that of normal in convalescent phase ( $P<0.05$ ). The levels of CysC, BUN and SCr in severe group were higher than in light group in different stages ( $P<0.05$ ). The Pearson correlation coefficient of CysC, BUN and SCr was 0.7688 and 0.8071, respectively ( $P<0.05$ ). There existed that serum CysC had a good positive correlation with BUN and SCr. **Conclusions:** Serum levels of CysC might be a sensitive indicator for kidney injury and be of prognostic importance in patients with HFRS.

**Key words:** Serum cystatin C; Hemorrhagic fever with renal syndrome; Kidney injury

Chinese Library Classification(CLC): R512.8 Document code: A

Article ID: 1673-6273(2014)28-5511-03

### 前言

肾综合征出血热(HFRS)是由汉坦病毒引起的一种自然疫源性疾病<sup>[1]</sup>,是我国重点防治传染病之一<sup>[2]</sup>,而肾脏损害是HFRS早期也是最主要的临床特征<sup>[3]</sup>。胱抑素(cystatin, CysC)作为近年新的内源性肾功能指标,是一个较为理想的反映内源性肾小球滤过率(glomerular filtration rate, GFR)指标<sup>[4]</sup>,其检测对诊断HFRS患者肾脏损害具有一定的临床实用价值<sup>[5]</sup>。本文通过分析临床各期及各型HFRS患者血清CysC、尿素氮

(BUN)及肌酐(SCr)的动态变化,旨在探讨血清CysC测定在HFRS患者肾功能评价中的应用。

### 1 材料与方法

#### 1.1 临床资料

研究对象为我院2010年10月-2013年6月收治的HFRS患者共106例(男86例,女20例,年龄18-68岁,平均年龄43岁)。诊断与分型根据卫生部颁布的《流行性出血热诊断标准及处理原则》<sup>[6]</sup>,其中轻型30例、中型54例、重型18例、危重型14例。入选标准:皆有典型临床表现,且血清HFRS特异性IgM抗体阳性,所有病例均排除既往有肾脏疾病史。分型标准:轻型、中型、重型、危重型。分期标准:发热期、低血压休克期、少尿期、多尿期和恢复期。为方便比较,将轻型与中型合并

作者简介:康岚(1984-),女,硕士,研究方向:感染病学,

电话:0451-86297420, E-mail:bingzhuyan@126.com

△通讯作者:颜炳柱,主治医师, E-mail:bingzhuyan@126.com

(收稿日期:2014-02-17 接受日期:2014-03-15)

为轻症组,重型与危重型合并为重症组。因低血压休克期持续短暂且常与少尿期重叠,故将此二期(称为极期)合并统计。正常对照组为90例(男62例,女28例,年龄19~71岁,平均年龄48岁),为我院健康体检者,肝肾功能指标正常且无肾脏疾病史。

### 1.2 方法

按病期(发热期、极期、多尿期和恢复期)采集血样,对照组人群血样一次性采集,样本存放-80℃低温冰箱待检;应用比浊法检测CysC;BUN(速率法)和SCr(酶法)测定采用PPD生化分析仪(美国Roche公司)。

### 1.3 统计学分析

全部数据采用SPSS13.0统计软件包处理,数据采用( $\bar{x} \pm s$ )

表示,采用组间t检验进行统计学分析,CysC与BUN、SCr的相关性用Pearson系数表示。显著性检验水准 $a=0.05$ , $P<0.05$ 时差异具有统计学意义。

## 2 结果

### 2.1 CysC与BUN、SCr在HFRS患者各期的变化

由表1可见,与对照组比较,各期CysC与BUN、SCr均明显增高( $P<0.05$ ),发热期开始升高,极期时达到最高值(峰值),多尿期时开始下降,恢复期明显降低。而CysC发热期( $2.27 \pm 0.73$ )mg/L与多尿期( $2.11 \pm 0.75$ )mg/L比较无显著差异( $P>0.05$ ),在恢复期时仍明显高于健康对照组( $P<0.05$ )。

表1 HFRS患者各期CysC、BUN与SCr水平比较

Table 1 Comparison of CysC, BUN and SCr in different phases of HFRS

Group	n	CysC(mg/L)	BUN (mmol/L)	SCr (umol/L)
Control group	90	0.65± 0.11	4.80± 1.08	67.88± 11.73
HFRS group	106			
Febrile phase		2.27± 0.73*	17.34± 8.28*	278.52± 142.70*
Hypotensive and oliguric phase		3.88± 1.29*	28.14± 12.95*	581.12± 272.00*
Diuretic phase		2.11± 0.75*△	14.08± 6.13*	196.92± 93.95*
Convalescent phase		1.41± 0.47*	7.27± 2.26*	95.02± 24.84*

注:与对照组比较,\* $P<0.05$ ;与发热期比较,△ $P>0.05$ 。

Note: compared with control group, \* $P<0.05$ ; compared with febrile phase, △ $P>0.05$ .

### 2.2 不同临床类型HFRS患者CysC与BUN、SCr水平比较

由表2可见,与对照组比较,轻症组与重症组CysC与BUN、SCr均明显高于对照组( $P<0.05$ );重症患者组在病程各

期CysC与BUN、SCr水平均明显高于轻症患者组,差异均有显著性( $P<0.05$ )。而发热期轻症组、重症组患者CysC水平分别与多尿期比较,差异无显著性( $P>0.05$ )。

表2 不同临床类型HFRS患者CysC、BUN与SCr的水平比较

Table 2 Comparison of CysC, BUN and SCr in different stages of HFRS

Group	n	CysC(mg/L)	BUN (mmol/L)	SCr (umol/L)
Control group	90	0.65± 0.11	4.80± 1.08	67.88± 11.73
HFRS Light group	74			
Febrile phase		2.05± 0.55*	14.72± 5.25*	221.11± 79.60*
Hypotensive and oliguric phase		3.40± 1.13*	22.89± 8.42*	448.2± 198.54*
Diuretic phase		1.91± 0.62*△	12.72± 5.70*	177.04± 81.11*
Convalescent phase		1.31± 0.43*	6.95± 2.21*	89.22± 18.72*
HFRS Severe group	32			
Febrile phase		2.78± 0.84**	23.42± 10.65**	411.28± 167.31**
Hypotensive and oliguric phase		4.73± 1.16**	40.29± 13.52**	888.49± 134.43**
Diuretic phase		2.58± 0.82**△	17.20± 6.01**	242.78± 106.21**
Convalescent phase		1.64± 0.48**	8.01± 2.22**	108.47± 37.59**

注:与对照组比较,\* $P<0.05$ ;与轻症组比较,\*\* $P<0.05$ ;与发热期比较,△ $P>0.05$ 。

Note: Compared with control group, \* $P<0.05$ ; compared with light group, \*\* $P<0.05$ ; compared with febrile phase, △ $P>0.05$ .

### 2.3 HFRS患者血清CysC与BUN、SCr水平相关性分析

将血清CysC与BUN、SCr测得的相应值进行相关处理,以CysC为横坐标作散点图,并求相关系数(r)。图1A示CysC

与BUN的相关关系,图1B示CysC与SCr的相关关系,其相关系数分别( $r=0.7688$ 和 $r=0.8071$ , $P<0.05$ )。结果表明CysC与BUN、SCr呈高度正相关。




图 1 HFRS 患者 CysC 与 BUN、SCr 的相关关系  
Fig.1 The correlation between CysC and BUN、SCr in patients of HFRS

### 3 讨论

汉坦病毒引起的肾综合征出血热(HFRS),其病理损伤表现为多脏器组织小血管的广泛损害及功能失调,其中肾脏尤为明显、表现为急性肾功能衰竭<sup>[7]</sup>,也是导致患者死亡的主要原因之一<sup>[8]</sup>。肾小球滤过率(GFR)被认为是评价肾小球滤过功能最客观的指标,尽管尿素氮、肌酐等标志物在临幊上评价肾功能时应用比较广泛,但因其影响因素较多,在评估 GFR 时存在着一定的不准确性。因此,寻找更为敏感且判断肾功损伤的生物学标志物,也是临幊研究的一个热点。

胱抑素(CysC)是一种半胱氨酸蛋白酶抑制剂,其相对分子量为 13Kd,基因编码位于 20 号染色体上<sup>[10]</sup>,几乎所有的有核细胞均能表达<sup>[11]</sup>,主要作用是保护细胞免受内源性或外源性蛋白酶水解。血清 CysC 水平主要由 GFR 决定,其机体的产生速率十分稳定,其血清浓度不受患者性别、身高、年龄及肌肉等因素影响,故 CysC 可以作为一个较理想的反映 GFR 变化的内源性标志物<sup>[12-13]</sup>。1985 年 CysC 首次被报道用于肾功能测定<sup>[14]</sup>,国内外相继研究结果均支持 CysC 可作为较 SCr 和 BUN 更好地反映 GFR 的内源性指标<sup>[15-17]</sup>。此外,近年来 CysC 作为评价肾功能损伤的指标,在多种肾脏损伤中日益得到关注与应用<sup>[18-20]</sup>。

本文研究表明 CysC 在发病早期就开始升高,在极期(低血压休克期或少尿期)时达到峰值,而多尿期时开始下降,恢复期明显降低,其消长趋势与 HFRS 疾病的发展过程基本一致,并且与 BUN 和 SCr 水平的变化相平行,与国内一些学者报道的相一致<sup>[21]</sup>。这一结果说明检测血清 CysC 变化可较敏感地反映 HFRS 患者肾脏损伤。而在不同临床类型的 HFRS 患者各期 CysC 变化中,表现为重症患者在病程各期 CysC 水平均明显高于轻症患者组,这提示 CysC 水平与病情轻重具有一定的相关性。因此,检测血清 CysC 水平对初步判断患者病情具有一定前瞻性。值得关注的是,CysC 在恢复期虽明显下降,但仍高于健康人群水平,相对滞后于 BUN 和 SCr 的恢复时间。

此外,本研究发现 CysC 与 BUN 和 SCr 有良好的统计相关性,提示 CysC 也能作为判断 HFRS 患者肾功能异常的良好指标。尽管 BUN 和 SCr 水平是反映 HFRS 患者病情的客观指标之一,但鉴于 HFRS 患者 CysC 也存在明显变化,因此联合血清 CysC 与 BUN 和 SCr,对判断和估计 HFRS 患者病情及预后

有着一定的临床价值,而且 CysC 可作为一个更好的反映 HFRS 患者肾功能变化的内源性指标。

### 参 考 文 献(References)

- [1] Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease[J]. Clin Microbiol Rev, 2010, 23(2): 412-441
- [2] 黄立勇, 周航, 殷文武, 等. 2010 年中国肾综合征出血热监测及疫情分析[J]. 中华流行病学杂志, 2012, 33(7): 685-691  
Huang Li-yong, Zhou Hang, Ying Wen-wu, et al. The current epidemic situation and surveillance regarding hemorrhagic fever with renal syndrome in China, 2010[J]. Chin J Epidemiol, 2012, 33(7): 685-691 (In Chinese)
- [3] 李兰娟, 任红. 传染病学[M]. 8 版. 北京: 人民卫生出版社, 2013: 77-85  
Li Lan-juan, Ren Hong. Infectious diseases [M]. 8th ed. Beijing: People's Medical Publishing House, 2013: 77-85 (In Chinese)
- [4] Inker LA, Okparavero A. Cystatin C as a marker of glomerular filtration rate: prospects and limitations [J]. Curr Opin Nephrol Hypertens, 2011, 20(6): 631-639
- [5] 杨渝伟, 曾平, 张林, 等. 慢性肾病患者基于血清胱抑素 C 与肌酐的肾小球滤过率估算的建立和评价[J]. 中华检验医学杂志[J]. 2013, 36(4): 352-359  
Yang Yu-wei, Zeng Ping, Zhang Lin, et al. Establishment and evaluation of estimated glomerular filtration rate by serum cystatin C alone and in combination with serum creatinine in patients with chronic kidney disease[J]. Clin J Lab Med, 2013, 36(4): 352-359 (In Chinese)
- [6] 卫生部疾病控制司《流行性出血热防治手册》编写组. 流行性出血热防治手册[M]. 第二版. 北京: 人民卫生出版社, 1998: 161-165  
Ministry of Health Disease Control Division. Epidemic hemorrhagic fever prevention and control manual [M]. 2nd ed. Beijing: People's Medical Publishing House, 1998: 161-165 (In Chinese)
- [7] Krautkramer E, Zeier M, Plyusnin A. Hantavirus infection: an emerging infectious disease causing acute renal failure [J]. 2013, 83(1): 23-27
- [8] 杨力生. 52 例重症肾综合征出血热的多器官功能障碍综合征临床分[J]析. 中国人兽共患病学报, 2012, 28(4): 410-411  
Yang Li-sheng. Cases of 52 severe hemorrhagic fever with renal syndrome and multiple organ dysfunction syndrome analysis [J]. Chinese Journal of Zoonoses, 2012, 28(4): 410-411 (In Chinese)

(下转第 5538 页)

- Hypertension, 2005, 46(9): 738-744
- [4] Mei Y, Jin H, Tian W, et al. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats [J]. Pulm Pharmacol Ther, 2011, 24(4): 386-393
- [5] Talija Djordjevic, Rachida S BelAiba, Steve Bonello, et al. Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle cells [J]. Arterioscler Thromb Vasc Biol, 2005, 25: 519-525
- [6] Ishihata A, Ogaki T, Aita T. Role of prostaglandins in urotensin II induced vasodilatation in the coronary arteries of aged rats [J]. Eur J Pharmacol, 2005, 523(1-3): 119-126
- [7] Gray GA, Jones MR, Isam S. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition[J]. Life Sciences, 2001, 69 (2): 175-180
- [8] Bito V, Heinzel FR, Biesmans L, et al. Cross talk between Ltype  $\text{Ca}^{2+}$  channels and the sarcoplasmic reticulum: alterations during cardiac remodelling[J]. Cardiovasc Res, 2008, 77(2): 315-324
- [9] Kawada T, Yamazaki T, Akiyama T, et al. Effects of  $\text{Ca}^{2+}$  channel antagonists on nerve stimulation-induced and ischemia-induced myocardial interstitial acetylcholine release in cats [J]. Am J Physiol Heart Circ Physiol, 2006, 291(5): H 2187-2191
- [10] Simonis G, Briem SK, Schoen S P, et al. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy [J]. Mol Cell Biochem, 2007, 305 (1-2): 103-111
- [11] Zhang YG, Li J, Li YG. Urotensin-II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta[J]. J Hypertens, 2008, 26(6): 1119- 1126
- [12] Zhang YG, Li YG, Liu BG, et al. Urotensin-II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol [J]. Acta Pharmacol Sin, 2007, 28(1): 36-43
- [13] Tzanidi SA, Hannan RD, Thomas WG, et al. Direct actions of Urotensin II on the heart: implications for cardiac fibrosis and Hypertrophy[J]. Circ Res, 2003, 93(3): 246-253
- [14] Onan D, Pipolo L, Yang E, et al. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases[J]. Mol Endocrinol, 2004, 18(9): 2344-2354
- [15] Papadopoulos P, Bousette N, Giard A. Urotensin-II and cardiovascular remodeling[J]. Peptides, 2008, 29(5): 764-769
- [16] Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin II is raised in hypertension [J]. Hypertension, 2004, 42(7): 1341-1344
- [17] Shepherd J T, Zvonimir S. Endothelium derived vasoactive factor. Endothelium dependent relaxation[J]. Hypertension, 1991, 18: 76
- [18] Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma [J]. Biochem Biophys Res Commun, 1993, 192(2): 553-560
- [19] Sugo S, Minamino N, Kangawa K, et al. Endothelial cells actively synthesize and secrete adrenomedullin [J]. Biochem Biophys Res Commun, 1994, 201: 1160-1166
- [20] 石向东, 吕志梁, 唐朝枢, 等. 尾加压素Ⅱ促血管内皮细胞分泌肾上腺髓质素的作用[J]. 中华心血管病杂志, 2005, 33(9): 836-839  
Shi Xiang-dong, Lv Zhi-liang, Tang Chao-shu, et al. Urotensin II vascular endothelial cell secretion of adrenomedullin [J]. Chinese Journal of cardiovascular disease, 2005, 33(9): 836-839

(上接第 5513 页)

- [9] 陈文彬, 潘祥林. 诊断学 [M]. 7 版. 北京: 人民卫生出版社, 2011: 349-349  
Chen Wen-bin, Pan Xiang-lin. Diagnosis [M]. 7th ed. Beijing: People's Medical Publishing House, 2013: 349-349 (In Chinese)
- [10] Crubb AO. Cystatin c-properties and use as diagnostic marker [J]. Adv Clin Chem, 2000, 35: 63-99
- [11] Nitta K, Hayashi T, Uchida K, et al. Serum cystatin C concentration as a marker of glomerular filtration rate in patients with various renal diseases[J]. Intern Med, 2002, 41(11): 931-935
- [12] Murty MS, Sharma UK, Pandey VB, et al. Serum cystatin C as a marker of renal function in detection of early acute kidney injury[J]. Indian J Nephrol, 2013, 23(3):180-183
- [13] Symonides B, Wieteska M, Bobilewicz D. The usefulness of plasma cystatin c determination as a marker of glomerular filtration rate[J]. Przegl Lek, 2007, 64(1):54-58
- [14] Simonsen O, Grubb A, Thysell H. The blood concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate[J]. Scand J Clin Lab Invest, 1985, 45(2): 97-101
- [15] Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function [J]. N Engl J Med, 2013, 369(10): 932-943
- [16] Christensson A, Ekberg J, Grubb A, et al. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation.
- Nephron Physiol[J]. 2003; 94(2):19-27
- [17] 李强, 王维平, 房洁渝, 等. 肌酐监测休克患者急性肾损伤的研究[J]. 中华急救医学杂志, 2010, 19(10): 1074-1077  
Li Qiang, Wang Wei-ping, Fang Jie-yu, et al. Study of CysC and Scr used to evaluate acute renal injury of patients with shock [J]. Chin J Emerg Med, 2010, 19(10):1074-1077 (In Chinese)
- [18] Krishnamurthy N, Arumugasamy K, Anand U, et al. Serum cystatin c levels in renal transplant recipients [J]. Indian J Clin Biochem, 2011, 26(2): 120-124
- [19] Gheissari A, Rezaei Z, Merrikhi A, et al. Association of neutrophil gelatinase associated lipocalin and cystatin c with kidney function in children with nephritic syndrome [J]. Int J Prev Med, 2013, 4(8): 956-963
- [20] 肖玉联, 邓会英. 血清胱抑素 C 在危重患儿急性肾损伤早期诊断中的临床价值[J]. 中国综合临床, 2013, 29(6):574-576  
Xiao Yu-lian, Deng Hui-ying. The value of serum cystatinc in the early diagnosis of acute kidney injury in critically ill children [J]. Clinical Medicine of China, 2013, 29(6): 574-576 (In Chinese)
- [21] 代瑛, 沈建军, 张喆, 等. 肾综合征出血热患者血清 Cys-C 测定临床意义[J]. 陕西医学杂志, 2011, 40(7): 884-886  
Dai Ying, Shen Jian-jun, Zhang Zhe, et al. The value of serum cystatin C detection in sera from patients with hemorrhagic fever with renal syndrome [J]. Shanxi Medical Journal, 2011, 40 (7): 884-886 (In Chinese)